Inactive Instrument

US Rare Earth Minerals Inc Stock Other OTC

US9034101082

Biotechnology & Medical Research

End-of-day quote Other OTC
- ^USD	-

08-14	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-11	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI

Valuation : US Rare Earth Minerals Inc

Market Cap	2.66M 2.29M 2.17M 1.96M 3.69M 254M 3.7M 25.74M 9.9M 129M 9.98M 9.76M 408M	P/E 2024	-5.27x	P/E 2025	-3.28x
Enterprise Value	3.4M 2.93M 2.77M 2.51M 4.71M 325M 4.74M 32.92M 12.66M 165M 12.76M 12.48M 522M	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99.38%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : US Rare Earth Minerals Inc

08-14	Bioxytran, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-11	Bioxytran Reports Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy Patient Treated with PLICID	CI
08-04	Bioxytran, Inc. and University Of Minnesota Department Of Chemistry Execute Second Sponsored Research Agreement To Advance ASI-Powered Carbohydrate Drug Design Platform	CI
07-30	US officials pressed China on rare earths, farm goods commitments, Bessent says	RE
07-29	Bioxytran Announces Publication of Corporate Research Report Discussing Prolectin-M Phase 2 Results, Planned 408-Patient Registrational Trial, Bxt-25 Oxygen-Therapeutic Platform, and A-Suqar Commercial Distribution Agreement	CI
07-16	Italy's Angelini Pharma completes $4.1 billion state-backed takeover of Catalyst	RE
05-15	Bioxytran, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-15	Bioxytran, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-14	Bioxytran, Inc. Auditor Raises 'Going Concern' Doubt	CI
03-17	Bioxytran, Inc. announced that it has received $1.158942 million in funding	CI
03-04	Bioxytran Inc Announces Positive Dose Optimization Results And Advances Toward Phase 3 Registrational Trial For ProLectin-M	CI
03-02	Bioxytran Inc reports positive phase 1b/2a clinical study results for Prolectin-M, broad-range antiviral drug in mild to moderate Covid-19	RE
02-17	Bioxytran, Inc. Announces Commercial Distribution Agreement with Khoury Medical Ltd for A-SUQAR Dietary Supplement	CI

More news

Press Releases : US Rare Earth Minerals Inc

08-11	Bioxytran Reports Encouraging Clinical Observations in First Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patient Treated with PLICID, a Novel Galectin Antagonist Designed with Artificial Intelligence	AQ
08-04	Bioxytran Leverages Artificial Super Intelligence (ASI) to Design Broad-Spectrum Antiviral and Anti-Cancer Metastasis Drugs	AQ
07-29	Bioxytran Announces Publication of Corporate Research Report by Globe Small Cap Research	AQ
05-29	Bioxytran Highlights New Book on Real-Time Monitoring Tissue Oxygenation Relevant to Oxygen Carrier BXT-25	AQ
03-20	BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT	AQ

More press releases

Managers and Directors : US Rare Earth Minerals Inc

Manager	Title	Age	Since
David Platt CEO	Chief Executive Officer	73	2018-08-31
Ola Soderquist DFI	Director of Finance/CFO	65	2018-08-31
Leslie Ajayi CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Dale Conaway BRD	Director/Board Member	71	2018-11-01
Alan Hoberman BRD	Director/Board Member	73	2018-11-01
David Platt CHM	Chairman	73	2018-08-31

More insiders

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with intended applications, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

Employees

Sector

Biotechnology & Medical Research

More about the company

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!

SEIZE THE OFFER!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.11%	-1.68%	+44.52%	+95.15%	66.93B
ARGENX SE	-0.23%	-4.45%	+30.39%	+73.64%	61.97B
INSMED INCORPORATED	+1.67%	+2.47%	-11.23%	+388.34%	28.27B
WUXI BIOLOGICS (CAYMAN) INC.	-1.05%	-4.43%	+30.56%	+10.07%	24.59B
BIONTECH SE	+0.34%	-6.78%	-7.27%	-17.99%	24.3B
GENMAB A/S	+0.43%	-3.37%	+14.85%	-19.29%	19.41B
PHARMAESSENTIA CORPORATION	-3.03%	-2.29%	+185.12%	+334.07%	16.77B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.94%	-4.94%	-5.29%	+495.65%	14.18B
EXELIXIS, INC.	-2.28%	-4.90%	+43.64%	+155.21%	13.91B
Average	-0.91%	-3.46%	+36.14%	+168.32%	30.04B
Weighted average by Cap.	-0.84%	-3.06%	+33.46%	+133.67%

	2024	2025
Net sales	-	-
Net income	-2.37M -2.04M -1.93M -1.75M -3.28M -226M -3.3M -22.93M -8.82M -115M -8.89M -8.69M -363M	-2.12M -1.83M -1.73M -1.57M -2.95M -203M -2.96M -20.57M -7.91M -103M -7.97M -7.8M -326M
Net Debt	1.09M 938K 888K 805K 1.51M 104M 1.52M 10.55M 4.06M 52.93M 4.09M 4M 167M	741K 638K 604K 548K 1.03M 70.77M 1.03M 7.18M 2.76M 36M 2.78M 2.72M 114M

US Rare Earth Minerals Inc Stock Other OTC

Stocks

US9034101082

Biotechnology & Medical Research

Valuation : US Rare Earth Minerals Inc

Latest news : US Rare Earth Minerals Inc

Press Releases : US Rare Earth Minerals Inc

Managers and Directors : US Rare Earth Minerals Inc

Bio Therapeutic Drugs

Financials

Company Profile